Status:
COMPLETED
Safety and Efficacy of Lactococcus Lactis Probiotic Bacteria for the Treatment of Chronic Rhinosinusitis
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborating Sponsors:
McGill University
Conditions:
Chronic Rhinosinusitis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Despite advances in medical treatments and surgery for chronic rhinosinusitis (CRS), there remains a large number of patients who continue to suffer from chronic sinusitis despite standard therapies. ...
Detailed Description
CONTEXT/JUSTIFICATION: Chronic rhinosinusitis (CRS) is one of the most frequent chronic diseases and has a significant negative impact on quality of life (QOL) in patients who suffer from it. Despite...
Eligibility Criteria
Inclusion
- refractory chronic rhinosinusitis (CRS)
- persistence of symptoms of CRS despite previous endoscopic sinus surgery (ESS) and ongoing medical management
Exclusion
- patients \<18 years
- cystic fibrosis
- technical reasons for ESS failure
- active sinus infection with purulence pain and/or hyperthermia
- immune suppression from disease or medication.
Key Trial Info
Start Date :
March 6 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 2 2015
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04048174
Start Date
March 6 2013
End Date
December 2 2015
Last Update
August 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2X 1P1